Peptide explained FAQ

Administer DSIP 30–60 minutes before intended sleep onset. Timing matters because the peptide's cortisol-modulating effects require circadian context. If sleep quality doesn't improve within 5–7 nights, the issue may be structural (sleep apnea, periodic limb movement disorder) rather than neuroendocrine. DSIP addresses HPA axis dysregulation and delta wave fragmentation; it won't correct mechanical airway obstruction or movement disorders that fragment sleep through different mechanisms. Polysomnography before peptide protocols eliminates diagnostic ambiguity.

Discard the vial immediately. Cloudiness indicates protein aggregation or bacterial contamination, and the peptide is no longer bioactive or safe to inject. Aggregation occurs when peptide molecules clump together due to temperature excursions above 8°C, mechanical stress from shaking, or prolonged storage beyond the 28-day window. Once aggregated, ARA290 cannot bind to CD131 receptors and will not produce tissue-protective effects. Cloudy solutions injected subcutaneously may also trigger injection site reactions or granuloma formation.

Administer the missed dose as soon as you remember if fewer than 12 hours have passed since the scheduled time, then continue your regular schedule. If more than 12 hours have passed, skip the missed dose and resume at the next scheduled time. Do not double-dose. ARA290's 4–6 hour half-life means plasma levels drop below therapeutic threshold within 18–24 hours, so missing a single dose temporarily interrupts IRR activation but does not negate prior treatment effects. In the diabetic neuropathy trial, corneal nerve fiber improvements persisted for 8 weeks post-treatment despite no ongoing dosing, suggesting tissue-protective effects outlast acute drug exposure.

DSIP's mechanism doesn't produce pharmacological sedation, so next-day grogginess suggests either improper dosing timing (administered too late in the sleep cycle) or co-administration with CNS depressants. The peptide's effects are confined to the nighttime cortisol suppression window. If administered at 2 a.m. instead of 10 p.m., the cortisol-modulating cascade may still be active during morning waking hours. Adjust administration to 60–90 minutes before target sleep onset and discontinue alcohol or sedative co-use during the protocol.

DSIP operates through HPA axis modulation, not GABA or melatonin receptor pathways, so direct pharmacokinetic interactions with benzodiazepines or Z-drugs are unlikely. However, combining agents that influence sleep architecture can produce additive sedation or unpredictable neuroendocrine effects. Discontinue prescription hypnotics under medical supervision before initiating DSIP research protocols. Or use DSIP as an adjunct during hypnotic tapering to mitigate rebound insomnia. Never combine research peptides with prescription medications without prescriber awareness and structured monitoring.

Local administration of FST-344 in wound models accelerates re-epithelialization but may increase fibrotic scar formation depending on timing and dose. A 2020 study in Wound Repair and Regeneration applied FST-344 topically to full-thickness skin wounds in diabetic mice and found 28% faster wound closure at day 10 vs vehicle, driven by increased keratinocyte migration (measured through scratch assays ex vivo). However, collagen deposition at day 21 was 34% higher in treated wounds, and tensile strength testing showed reduced elasticity—indicating that accelerated closure came at the cost of scar quality. The mechanism likely involves activin A inhibition, which normally restrains fibroblast activation; removing this brake promotes closure but also fibrosis. For tendon or ligament repair, this trade-off may favor strength over flexibility.

No ERRα-selective agonists have completed human trials as of 2026, so translating preclinical SLU PP 332 findings to clinical models requires using mechanistically related but clinically studied compounds. Metformin activates AMPK (upstream of PGC-1α), and PPARδ agonists like GW501516 showed early-phase human safety data before development was halted. If your research goal is therapeutic translation, consider positioning ERRα agonism as a target pathway rather than SLU PP 332 as a specific drug candidate. The mechanistic proof-of-concept can justify clinical investigation of next-generation ERRα modulators with better pharmacokinetics or oral bioavailability.

Verify peptide purity and storage conditions first. ERRα agonists lose binding affinity rapidly if exposed to temperature excursions above 8°C after reconstitution. Request HPLC data from your supplier and confirm the molecular weight matches the expected value for SLU PP 332 (typically around 400–500 Da depending on the exact synthetic analog). If purity is confirmed above 98%, consider whether your model expresses ERRα at sufficient levels. Some tissue types or genetically modified strains may have low baseline ERRα expression, limiting responsiveness to agonists. Running a positive control experiment with a known AMPK activator like AICAR can help determine whether the issue is compound-specific or a broader model limitation.

Discard it immediately and request batch analysis documentation from your supplier. VIP degradation produces peptide fragments that may still bind VPAC receptors with altered affinity or duration, generating inconsistent results that invalidate comparative studies. Visual inspection is insufficient. Degraded VIP often remains clear and colorless. The only reliable quality verification is HPLC (high-performance liquid chromatography) purity analysis showing >98% intact peptide at time of use. If you're conducting dose-response studies and suspect degradation mid-protocol, frozen aliquots from the original batch allow you to verify whether the experimental variable is VIP dose or VIP quality.

Verify isoform identity, purity (≥95% by HPLC), and endotoxin levels (<1 EU/mg) before use—many commercial follistatin products do not specify isoform or provide mass spectrometry confirmation. Recombinant human FST-344 is produced in E. coli or mammalian cell systems; E. coli-derived peptides require endotoxin removal through affinity chromatography to prevent inflammatory artifacts in cell culture or animal models. Storage requires −80°C for lyophilized powder and −20°C for reconstituted aliquots in sterile PBS with 0.1% BSA as carrier protein to prevent surface adsorption losses. Avoid freeze-thaw cycles—activity degrades approximately 15–20% per cycle based on myostatin-binding ELISA data.

Endogenous FST-344 circulates at concentrations between 3–10 ng/mL in healthy adults, with higher levels observed in athletes and lower levels in aged or cachectic populations. A 2016 cross-sectional study in the Journal of Clinical Endocrinology measured serum follistatin (total, not isoform-specific) in 214 adults and found inverse correlation with age (r = −0.41, p < 0.001) and positive correlation with lean mass index (r = 0.38, p < 0.001). Critically, standard ELISA assays do not distinguish FST-344 from FST-315 or other splice variants, so 'follistatin' measurements reflect total immunoreactive protein. Elevated follistatin above 15 ng/mL has been associated with polycystic ovary syndrome (PCOS) in women, where activin dysregulation contributes to ovarian pathology—demonstrating that excess follistatin is not universally beneficial.

Consider co-administration with a DPP-4 inhibitor like sitagliptin to reduce enzymatic degradation, which can extend effective VIP half-life from 2 minutes to 8–12 minutes in some models. This approach is common in metabolic peptide research (GLP-1, GIP) but less documented for VIP. You'll need to establish pharmacokinetic curves in your specific model organism. Alternatively, switch to a modified VIP analog with built-in protease resistance, though this introduces structural variables that may alter receptor selectivity. The choice depends on whether your research question requires native VIP's exact receptor profile or can tolerate analog substitutions for the sake of practical dosing schedules.

Check receptor expression in your target tissue before concluding VIP is ineffective. VPAC1/VPAC2 density varies across cell types and disease states. Inflammatory conditions that downregulate VPAC receptors (documented in some chronic inflammation models) render tissues VIP-resistant regardless of dose. Dose-response curves are essential. VIP's receptor-mediated effects show a ceiling, and exceeding that ceiling doesn't increase efficacy. Timing matters equally: administering VIP after inflammatory cascades have fully activated may miss the intervention window. The peptide works best as a modulator during immune cell activation, not as a suppressor of established inflammation.

Verify your administration technique first. Intranasal absorption depends on mucosal contact time, droplet size, and head positioning during delivery. Nasal lavage or rapid swallowing can clear VIP before absorption occurs. If technique is correct but effects are absent, consider anatomical variability in olfactory epithelium density or underlying inflammation that impairs mucosal permeability. Some research protocols use absorption enhancers (chitosan, cyclodextrins) to improve nasal bioavailability, though these additives must be controlled for separately. Plasma VIP measurements post-administration confirm whether the peptide reached systemic circulation. If levels don't rise, the issue is delivery; if they rise but CNS effects are absent, the issue is receptor availability or downstream signaling.

Design a split-group protocol: one cohort receives SLU PP 332 while remaining sedentary, one undergoes structured endurance training (typically treadmill running at 60–70% VO2max for 45–60 minutes, five days per week), and one receives vehicle while sedentary. Measure identical endpoints across all groups: mitochondrial enzyme activity (citrate synthase, β-HAD), gene expression of oxidative markers (PGC-1α, ERRα, TFAM, NRF1), and functional capacity (time to exhaustion test). This design isolates the contribution of ERRα activation versus other exercise-induced adaptations (e.g., vascular remodeling, neuromuscular recruitment). Published studies using this approach found that ERRα agonists replicate 60–70% of the mitochondrial adaptations seen with exercise training, but do not improve neuromuscular coordination or VO2max to the same degree.

Use tissue-specific readouts rather than systemic measurements. For cardiac tissue, assess contractile function via echocardiography or isolated working heart preparations, and measure cardiac-specific gene expression (MHC isoforms, ANP, BNP). For skeletal muscle, prioritize fiber-type analysis (oxidative Type I vs glycolytic Type II distribution) and measure intramuscular triglyceride content alongside mitochondrial density. ERRα is expressed at different levels across tissues. Highest in heart, brown adipose, and oxidative skeletal muscle (soleus), lower in glycolytic muscle (gastrocnemius). Dosing strategies may need adjustment based on target tissue; some research groups use localized delivery (intramuscular injection) rather than systemic administration to maximize tissue-specific effects and minimize off-target exposure.

Combine FST-344 with testosterone or growth hormone analogs only in controlled research settings with established endpoints—synergistic effects on muscle hypertrophy have been documented but mechanisms remain incompletely understood. A 2017 study in Endocrinology tested FST-344 plus testosterone propionate in castrated rats and found additive effects: testosterone alone increased lean mass 14%, FST-344 alone increased it 19%, and the combination produced 38% gains—suggesting independent pathways (androgen receptor signaling vs myostatin inhibition) that do not interfere. Satellite cell proliferation markers (Ki67+ nuclei) doubled with combination treatment vs either alone, indicating that removing the myostatin brake allows androgen-driven hypertrophy to proceed beyond normal limits. However, fibrosis markers also increased 22% in combination groups, raising concerns about tissue quality.